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Abstract
This topic addresses the management of recurrent Hodgkin lymphoma. While autologous stem cell 
transplantation may be appropriate for select cases of recurrent disease following comprehensive 
combined-modality therapy, other options exist for patients treated with lower-dose therapy for 
early-stage disease. Additionally, innovative targeted therapies provide newer salvage options to 
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consider. The American College of Radiology Appropriateness Criteria® are evidence-based 
guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert 
panel. The guideline development and revision include an extensive analysis of current medical 
literature from peer-reviewed journals and the application of well-established methodologies 
(RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, 
Development, and Evaluation, or GRADE) to rate the appropriateness of imaging and treatment 
procedures for specific clinical scenarios. In those instances where evidence is lacking or 
equivocal, expert opinion may supplement the available evidence to recommend imaging or 
treatment. By combining the most recent medical literature and expert opinion, this revised 
guideline can aid clinicians in the complex decisionmaking associated with the management of 
recurrent Hodgkin lymphoma.
Summary of Literature Review
Introduction/Background
Classical Hodgkin lymphoma is a highly curable cancer, even in advanced stages. Although 
radiation therapy (RT) alone improved disease-free survival (DFS) for many years, the 
management of classical Hodgkin lymphoma has changed dramatically over the past 2 
decades with the use of highly effective systemic therapies and the subsequent reduction in 
the use of radiation. [1] Even with combined-modality therapy (CMT), rates of relapse can 
vary from 5% for early-stage disease to 35% for more advanced stages.[2,3] Approximately 
10% of patients will have disease that is refractory to initial therapy.[4] Even in the setting of 
relapsed or refractory disease, classical Hodgkin lymphoma remains salvageable. The 
standard of care for relapsed/refractory disease is either conventional chemotherapy or high-
dose chemotherapy with autologous stem cell transplantation (HDCT + ASCT). The role of 
RT in relapsed/refractory disease remains controversial and is reviewed in these guidelines.
Definitions and Determination of Relapsed/Refractory Disease
Relapse or recurrence can be defined as the reappearance of disease after initial therapy and 
complete response (CR) in the site of prior disease and/or in new sites. Progression refers to 
evidence of increasing disease after achievement of stable disease, partial remission (PR), or 
CR, whereas refractory disease is a failure to achieve either a CR or PR and may represent a 
more significant degree of radiation or drug resistance.[5,6]
Current National Comprehensive Cancer Network guidelines recommend biopsy to 
document relapse, progression, or refractory disease.[7] Until recently, guidelines as to how 
to document progression of disease in the setting of incomplete remission remained unclear.
[8] Therefore, it is uncertain whether in practice biopsies are routinely performed according 
to this standard. However, biologic confirmation of disease is recommended. A biopsy may 
also be warranted in patients whose disease is refractory to therapy to confirm the initial 
diagnosis of classical Hodgkin lymphoma.
The majority of relapses following a CR in patients treated for classical Hodgkin lymphoma 
occur within 3 years of therapy, so routine surveillance by clinical examination is an 
essential component of a survivorship plan (see the ACR Appropriateness Criteria® Follow-
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up of Hodgkin Lymphoma[9]). The use of routine imaging after a CR is being challenged by 
recent studies,[10] so decisions regarding use can be made on an individual basis. A clear 
plan for surveillance is crucial, as timing of relapse has important prognostic significance 
and may impact treatment options.[3] Early relapse (< 12 months) is a poor prognostic factor 
and warrants more aggressive therapy. Other prognostic factors include localized vs 
disseminated disease and disease that has relapsed in previously irradiated areas.[11]
Management of Relapse Following Chemotherapy or CMT
HDCT + ASCT is the standard of care for relapsed/refractory classical Hodgkin lymphoma 
and can induce durable remissions in > 50% of patients.[12] No randomized trials have 
compared the effectiveness of salvage regimens for classical Hodgkin lymphoma, so 
selecting the appropriate regimen may be a challenge when considering both efficacy and 
toxicities. Because the goal of salvage chemotherapy is to achieve a second CR, usually a 
regimen different from that used for the initial course of therapy is administered.[13]
Some institutions favor platinum-based multidrug regimens, such as ICE (ifosfamide, 
carboplatin, and etoposide) or DHAP (dexamethasone, cytarabine, and cisplatin).[14,15] 
More recently, gemcitabine-based regimens[16,17] and the use of bendamustine[18] have 
been explored; these regimens are effective and well tolerated even in heavily pretreated 
patients. Gemcitabine-based regimens have been used both as primary salvage and for 
secondary salvage after ASCT.[16,18,19] Few studies have been done comparing the 
efficacy of different multidrug regimens. A small prospective study of 44 patients compared 
GDP (gemcitabine, dexamethasone, and cisplatin) with ESHAP (etoposide, 
methylprednisolone, cisplatin, and cytarabine); no difference was found in the response rate 
for relapsed/refractory Hodgkin lymphoma.[20]
Patients with relapsed or refractory disease after initial salvage have a median survival of < 3 
years with standard therapies. [21] Newer biologics and targeted therapies, such as 
brentuximab vedotin and nivolumab, may further improve survival. Brentuximab vedotin 
(SGN-35) is a CD30-directed antibody linked to monomethyl auristatin E, an antitubulin 
agent.[21] In a phase I trial, this potent antibody-drug conjugate was able to induce a CR or 
PR in 17 of 45 patients with relapsed or refractory disease who had been treated with 
multiple prior therapies.[22] The other 19 cases had stable disease after treatment. In a more 
recent multicenter, prospective, phase II study, the use of brentuximab enabled 86% of 
patients with relapsed/refractory Hodgkin lymphoma to proceed to ASCT.[23] The 
conjugate has also been shown to be effective in patients with relapsed/refractory disease 
after prior autologous or allogeneic stem cell transplantation, with overall response rates of 
75% and 50%, respectively.[24,25] Nivolumab is a programmed death 1 (PD-1)-blocking 
antibody that has considerable activity even in patients heavily pretreated for relapsed/
refractory Hodgkin lymphoma who had previously failed brentuximab vedotin.[26] Other 
targeted agents currently in development may also impact outcomes in the setting of 
relapsed/refractory classical Hodgkin lymphoma.[27]
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Role of RT in Hodgkin Lymphoma Salvage Programs
Poen et al[28] reported the results of a prospective trial evaluating the efficacy of involved-
field radiation therapy (IFRT) as part of the salvage regimen in patients selected for ASCT. 
Of 100 patients with relapsed/refractory classical Hodgkin lymphoma planning to proceed to 
ASCT, 24 received IFRT either before (n = 18) or after (n = 6) transplant. In patients with 
relapsed stage I-III classical Hodgkin lymphoma, the use of IFRT was associated with an 
improved 3-year freedom from relapse (100% vs 67%; P = .04) and a trend toward improved 
overall survival (OS) (85% vs 60%; P = .16).
Two additional contemporary retrospective studies also showed that IFRT following HDCT 
+ ASCT improves local control and survival in refractory disease, particularly in patients 
who have bulky disease at the time of relapse. [29,30] In one analysis, IFRT conferred 
benefits with respect to both 3-year OS (69.6% vs 40%) and disease-specific survival 
(82.1% vs 57.6%). [29] The timing of when to administer IFRT, either before or after ASCT, 
has been debated. When radiation is administered prior to ASCT, patients are more likely to 
receive the radiation as planned. Any marrow that may be in the field will be replaced once 
the patient’s transfused stem cells engraft, and there is a greater chance that the patient will 
enter ASCT with no residual disease. Some may prefer delivering radiation after ASCT to 
minimize the interval between the last dose of chemotherapy and ASCT, although several 
centers are accelerating the course of radiation to accommodate a quicker transition to 
ASCT. There is also a concern that radiation before ASCT may delay treatment plans 
because of increased toxicity; however, in the modern era, involved-site radiation therapy 
(ISRT) is the preferred method used in the management of both Hodgkin lymphoma and 
non- Hodgkin lymphoma,[31] and the smaller fields may reduce risk of acute treatment-
related toxicities.
Total lymphoid irradiation (TLI) can be utilized as part of conditioning regimens prior to 
ASCT. A recent study evaluated the use of positron emission tomography (PET)/computed 
tomography (CT) to predict outcomes of 51 patients treated for relapsed/refractory disease 
with TLI followed by HDCT + ASCT.[32] The 10-year progression-free survival (PFS) and 
OS rates were 56% and 54%, respectively. There are several ongoing clinical trials utilizing 
TLI as part of nonmyeloablative, reduced-intensity conditioning regimens for several 
hematologic disorders, including Hodgkin lymphoma (www.ClinicalTrials.gov). Some 
institutions have included total body irradiation (TBI) as part of the pretransplant 
conditioning regimen.[28,33,34] A feasibility study of tandem ASCT for relapsed/refractory 
classical Hodgkin lymphoma compared myeloablative regimens containing either busulfan 
or 12 Gy of TBI for patients making it to the second transplant.[33] Of the 43 patients 
enrolled, 32 received the second ASCT, with half receiving TBI. An additional 20 Gy of 
IFRT was included for 5 of these patients. In this particular study, the use of TBI did not 
increase risk of acute or late toxicities when compared with the group receiving 
chemotherapy alone.
Role of RT in Advanced-Stage Chemorefractory Hodgkin Lymphoma
Limited data are available on the role of consolidative RT in the setting of residual 
fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG) avidity following combination 
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chemotherapy for patients with advanced classical Hodgkin lymphoma. Sher et al[35] 
performed a retrospective analysis of 73 patients who received consolidative IFRT following 
systemic therapy to evaluate the prognostic significance of residual FDG avidity. The 
majority of patients (n = 60) were PET-negative at the end of ABVD (doxorubicin, 
bleomycin, vinblastine, and dacarbazine) therapy; the actuarial 2-year failure-free survival 
rate was 97% for this group, with 100% salvage for patients who relapsed. The 2-year 
failure-free survival rate was 69% for the PET-positive group with IFRT doses of ≥ 30 Gy, 
generating the hypothesis that the addition of RT may successfully sterilize local residual 
disease, thereby precluding the need to proceed immediately to salvage therapy in this 
setting.
In the European Organisation for Research and Treatment of Cancer (EORTC) 20884 trial, 
patients with stage III/IV classical Hodgkin lymphoma were treated with 6 to 8 cycles of 
MOPPABV (mechlorethamine, vincristine, procarbazine, and prednisone with doxorubicin, 
bleomycin, and vinblastine); patients who achieved a PR received 30-Gy IFRT.[36] The 
freedom from treatment failure (FFTF) and OS for this group were similar to patients who 
had achieved a CR in this study (5-year event-free survival, 79%; 5-year OS, 87%), 
suggesting that IFRT following a PR to systemic therapy improves outcomes.
Similarly, the German Hodgkin Study Group (GHSG) HD15 trial for patients with 
advanced-stage classical Hodgkin lymphoma administered 30-Gy IFRT to patients with 
PET-positive disease that measured ≥ 2.5 cm on CT scan after BEACOPP (bleomycin, 
etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone). [37] 
Of 311 patients who met criteria for enrollment, PET was positive in 66 patients; RT was 
recommended for 63. The PFS rate at 18 months was 96% for PET-negative patients and 
85% for PET-positive patients, indicating that IFRT for patients with persistently FDG-avid 
disease can successfully sterilize residual disease and may be a viable alternative to HDCT + 
ASCT.
Salvage Without Stem Cell Transplantation
Although HDCT + ASCT is the standard of care for relapsed/refractory classical Hodgkin 
lymphoma, several scenarios exist where alternative treatment strategies could be 
considered. These include patients with late relapse (> 1 year), patients who received limited 
frontline therapies such as RT or chemotherapy alone, or patients with early-stage disease 
treated with reduced-intensity therapy (eg, 2 cycles of ABVD followed by 20-Gy RT).
Relapse following RT alone—Historical series suggest that approximately 20% to 35% 
of patients with early-stage Hodgkin lymphoma treated with RT alone will relapse. [38,39] 
Yet there were many variables across studies, including staging with or without laparotomy, 
inclusion of patients with different prognostic factors, and differences in radiation field size, 
which may have impacted DFS and therefore make comparing studies a challenge. Ng et 
al[40] described out-comes of a single-institution prospective trial evaluating the use of 
mantle irradiation alone in patients with early-stage classical Hodgkin lymphoma. Patients 
with stage I-IIA classical Hodgkin lymphoma were enrolled in the study; patients with B 
symptoms, bulky disease, or subcarinal or hilar involvement were excluded. Mantle 
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radiation with doses ranging from 30 to 40 Gy was delivered from 1988 to 2000 in a cohort 
of patients with a median age of 30 years. Of the 87 patients enrolled, 13 (15%) relapsed, 
with most sites of relapse outside of the original treatment field. Half of the patients were 
salvaged with ABVD alone; the other half had CMT with IFRT. Only 1 patient experienced 
a second relapse and underwent salvage with HDCT followed by stem cell transplantation 
(SCT).[40]
An earlier retrospective study from MD Anderson Cancer Center enrolling patients 
beginning in 1967 included patients with unfavorable disease, including bulky tumor, > 4 
sites of disease, and/or B symptoms.[41] The 10-year PFS rate following mantle irradiation 
for this cohort that included patients with higher-risk disease was 75.3%. However, 10- and 
20-year actuarial OS rates were 87.6% and 65.3%, respectively, confirming highly 
successful salvage rates after treatment with radiation alone.
Although the use of RT as a primary treatment of classical Hodgkin lymphoma is no longer 
the standard of care, for the small cohort of patients previously treated with RT alone, it is 
still important to bear in mind that chemotherapy alone or with RT may be sufficient for 
salvage. However, limited data exist to provide definitive treatment recommendations.
Relapse following reduced-intensity therapy for early-stage disease—Reduced-
intensity therapy with 2 cycles of ABVD followed by 20-Gy IFRT for patients with 
favorable early-stage classical Hodgkin lymphoma provides favorable outcomes, with a 
FFTF rate of 91.1% at 5 years.[2] Since relapse in this very favorable group is uncommon, 
decisions must be made regarding the appropriate salvage therapies. Little data exist 
regarding the best salvage options in this setting.
The GHSG assessed results of salvage therapy in 42 patients out of 1,129 who were enrolled 
in 3 different prospective trials evaluating the use of 2 cycles of ABVD followed by IFRT.
[11] About 50% of these patients experienced an infield relapse, and a variety of salvage 
regimens were employed, including chemotherapy, HDCT + ASCT, and RT alone. In this 
small cohort, which had a median follow-up of 3 years, the OS rate was 67% following 
salvage therapy. Although this small report provides some insight into salvage following 
reduced-intensity therapy, additional prospective studies are needed to define the optimal 
salvage regimen in this cohort. In the meantime, extrapolation from these data regarding 
treatment of relapses with either chemotherapy or RT alone should help make informed 
decisions.
Relapse following chemotherapy alone—In the modern era, most patients diagnosed 
with Hodgkin lymphoma receive chemotherapy as part of initial therapy, either with or 
without consolidative RT. Treatment options at the time of relapse will vary based on a 
variety of prognostic features, the most significant of which are the presence of refractory 
disease and early and advanced relapses.[42]
Despite evidence suggesting that the addition of RT to systemic therapy improves tumor 
control and OS in patients with early-stage classical Hodgkin lymphoma,[34,43] efforts are 
still underway to validate the use of chemotherapy alone as a means to decrease late 
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treatment-related toxicities. One retrospective study reports the results of patients with early-
stage classical Hodgkin lymphoma who were treated with chemotherapy alone from 1992 to 
2008.[44] Bulky disease was excluded and eligible patients received 6 cycles of ABVD. All 
71 of the patients included in the study achieved a CR. At a median follow-up of 60 months, 
there were 6 relapses (8%), all at the site of presenting disease. Five of the relapses occurred 
within the first 2 years after a CR, and salvage consisted of CMT followed by ASCT.
It bears mentioning that salvage RT alone may be sufficient in these patients with local 
recurrence. Josting et al[45] reported the results of salvage RT for patients enrolled in GHSG 
trials from 1988 to 1999 who relapsed; most had been treated with COPP 
(cyclophosphamide, vincristine, procarbazine, and prednisone)/ABVD-like regimens. 
Salvage RT was used to treat patients at the time of initial relapse; the treatment field varied 
but mantle or IFRT was most often applied. Of the 100 patients, 77 achieved a CR. Sixty-
eight of these patients (88%) had stage I/II disease. [45] In this largest series evaluating use 
of salvage RT, the 5-year FFTF and OS rates were 28% and 51%, respectively, highlighting 
the need for appropriate patient selection.
Likewise, the management of patients who initially received chemotherapy alone for early-
stage disease and then relapsed locally must be carefully considered when outlining a 
treatment plan. Although ASCT has been shown to improve OS in relapsed classical 
Hodgkin lymphoma, it may not be necessary in this particular cohort of patients. [42] For 
each case, the long-term toxicity of additional chemotherapy must be weighed against that 
of modern RT (see Variants 1-6).
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• Hodgkin lymphoma is a highly curable disease, even in the relapsed setting.
• Although the standard of care for relapsed disease remains salvage therapy 
followed by ASCT, other alternatives exist in the modern era.
• Biologics and targeted agents such as brentuximab vedotin and nivolumab 
offer alternative systemic therapies that may get patients to ASCT faster and 
with less toxicity.
• The role of RT in the relapsed setting remains controversial, but prognostic 
factors such as timing and extent of relapse may help guide clinical decision 
making.
• In selected patients with small isolated relapses that occur > 3 years after 
initial presentation, consideration may also be given to a course of RT alone 
or CMT without transplant.
• RT is particularly indicated as part of CMT for patients with local relapse 
after treatment with chemotherapy alone or for relapses outside of the original 
site of disease; in this setting, ASCT may be deferred.
• ASCT should be considered for all patients with early relapsed or progressive 
disease while on therapy. If there is a PR to salvage chemotherapy, RT may be 
given pretransplant to achieve a CR.
• If a patient has a CR and the timing of RT is not dictated by a clinical trial, 
consolidative RT after ASCT allows the patient to proceed with therapy that is 
proven to improve OS.
• Modern radiation techniques, smaller treatment field, and lower overall doses 
help improve the therapeutic ratio of RT.
• Decisions regarding the best options in the relapsed setting should be made in 
the multidisciplinary setting.
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VARIANT 1.
25-year-old woman with CS IA (right neck) NSHL was treated with 2 cycles of ABVD + 20-Gy IFRT and 
achieved a CR. Two years after completion of treatment, a new 3-cm node was palpated in left neck. (Late 
nodal relapse after reduced-intensity therapy.)
Treatment Rating Comments
Evidence for relapse or refractory disease
 Requires pathologic confirmation 9
Recommended treatment
 RT alone 4
 Salvage chemotherapy alone 6
 Salvage chemotherapy + RT 7
 Salvage chemotherapy + SCT 6 SCT has treatment-related morbidity but may be 
appropriate in this clinical scenario.
 Salvage chemotherapy + RT + SCT (CR to salvage chemotherapy) 5
Volume of RT (after CR to chemotherapy)
 RT (ISRT) to site of relapse 8
 Adjuvant RT to recurrent and all previously untreated nodal sites (TLI) 2
Timing of RT
 Primary therapy 4
 Following salvage chemotherapy, if no SCT 8
RT dose (CR to salvage chemotherapy)
 < 30 Gy 4 There are limited data on low dose in this setting.
 30–36 Gy 7
 > 36 Gy 4
Rating Scale: 1,2,3 = usually not appropriate; 4,5,6 = may be appropriate; 7,8,9 = usually appropriate.
ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; CR = complete response; CS = clinical stage; IFRT = involved-field radiation 
therapy; ISRT = involved-site radiation therapy; NSHL = nodular sclerosis Hodgkin lymphoma; RT = radiation therapy; SCT = stem cell 
transplantation; TLI = total lymphoid irradiation.
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VARIANT 2.
25-year-old woman with CS IIA (bilateral neck) NSHL was treated with 4 cycles of ABVD alone and 
achieved a CR. Two years after completion of treatment, a new 3-cm node was palpated in left neck. (Late 
nodal relapse after chemotherapy alone.)
Treatment Rating Comments
Evidence for relapse or refractory disease
 Requires pathologic confirmation 9
Recommended treatment
 RT alone 4
 Salvage chemotherapy alone 4
 Salvage chemotherapy + RT 7
 Salvage chemotherapy + SCT 5
 Salvage chemotherapy + RT + SCT (CR to salvage chemotherapy) 5
Volume of RT (after CR to chemotherapy)
 RT (ISRT) to site of relapse 8
 Adjuvant RT to recurrent and all previously untreated nodal sites (TLI) 3
Timing of RT
 Primary therapy 3 There are limited data to address this question.
 Following salvage chemotherapy, if no SCT 7
 After salvage chemotherapy, before SCT (CR to salvage chemotherapy) 6
 After SCT 7 Some clinical trials dictate timing of RT
RT dose (CR to salvage chemotherapy)
 < 30 Gy 4
 30–36 Gy 8
 > 36 Gy 4
Rating Scale: 1,2,3 = usually not appropriate; 4,5,6 = may be appropriate; 7,8,9 = usually appropriate.
ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; CR = complete response; CS = clinical stage; ISRT = involved-site radiation 
therapy; NSHL = nodular sclerosis Hodgkin lymphoma; RT = radiation therapy; SCT = stem cell transplantation; TLI = total lymphoid irradiation.
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VARIANT 3.
25-year-old woman with CS IIIA (neck, mediastinum, and para-aortic) NSHL was treated with 6 cycles of 
ABVD alone and achieved a CR. Six months after completion of treatment, a new 3-cm node was palpated in 
left neck. (Early nodal relapse after chemotherapy alone.)
Treatment Rating Comments
Evidence for relapse or refractory disease
 Requires pathologic confirmation 9
Recommended treatment
 RT alone 2
 Salvage chemotherapy alone 3
 Salvage chemotherapy + RT 5
 Salvage chemotherapy + SCT 7
 Salvage chemotherapy + RT + SCT (CR to salvage chemotherapy) 8
Volume of RT (after CR to chemotherapy)
 RT (ISRT) to site of relapse 8
 Adjuvant RT to recurrent and all previously untreated nodal sites (TLI) 3 In this scenario, TLI is not referring to conditioning for 
SCT Consider whether it is appropriate to use TLI as 
adjuvant therapy.
Timing of RT
 Primary therapy 2
 Following salvage chemotherapy, if no SCT 7
 After salvage chemotherapy, before SCT (CR to salvage chemotherapy) 7
 After SCT 7
RT dose (CR to salvage chemotherapy)
 < 30 Gy 4
 30–36 Gy 8
 > 36 Gy 5
Rating Scale: 1,2,3 = usually not appropriate; 4,5,6 = may be appropriate; 7,8,9 = usually appropriate.
ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; CR = complete response; CS = clinical stage; ISRT = involved-site radiation 
therapy; NSHL = nodular sclerosis Hodgkin lymphoma; RT = radiation therapy; SCT = stem cell transplantation; TLI = total lymphoid irradiation.
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VARIANT 4.
25-year-old woman with CS IIIAX (neck, bulky mediastinum, upper para-aortic) NSHL was treated with 
ABVD × 6 and IFRT (30 Gy to the mediastinum).Three years after completion of therapy, chest CT showed 
new mediastinal adenopathy with bilateral lung nodules. (Possible late relapse after combined-modality 
therapy.)
Treatment Rating Comments
Evidence for relapse or refractory disease
 Requires pathologic confirmation 9
Recommended treatment
 RT alone 1
 Salvage chemotherapy alone 4
 Salvage chemotherapy + RT 3
 Salvage chemotherapy + SCT 8
 Salvage chemotherapy + RT + SCT (CR to salvage chemotherapy) 5
Volume of RT (after CR to chemotherapy)
 RT (ISRT) to mediastinum 5
 Adjuvant RT to recurrent and all previously untreated nodal sites (TLI) 3
Timing of RT
 Primary therapy 2
 Following salvage chemotherapy, if no SCT 5 This option is indicated if there is a CR to salvage 
chemotherapy.
 After salvage chemotherapy, before SCT (CR to salvage chemotherapy) 6
 After SCT 7
RT dose to mediastinum (CR to salvage chemotherapy)
 < 30 Gy 6
 30–36 Gy 6
 > 36 Gy 4
Rating Scale: 1,2,3 = usually not appropriate; 4,5,6 = may be appropriate; 7,8,9 = usually appropriate.
ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; CR = complete response; CS = clinical stage; CT = computed tomography; IFRT = 
involved-field radiation therapy; ISRT = involved-site radiation therapy; NSHL = nodular sclerosis Hodgkin lymphoma; RT = radiation therapy; 
SCT = stem cell transplantation; TLI = total lymphoid irradiation.
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VARIANT 5.
25-year-old woman with CS IIIAX (neck, bulky mediastinum, upper para-aortic) NSHL was treated with 
ABVD. After 6 cycles of ABVD, no significant decrease in mediastinal abnormality was seen and a new 
axillary node was palpated. (Progression on chemotherapy.) PET Deauville 5.
Treatment Rating Comments
Evidence for relapse or refractory disease
 Requires pathologic confirmation 8 Pathologic confirmation should help differentiate 
between relapse, follicular hyperplasia, infection, and 
transformation.
Recommended treatment
 RT alone 2
 Salvage chemotherapy alone 3
 Salvage chemotherapy + RT 3
 Salvage chemotherapy + SCT 7
 Salvage chemotherapy + RT + SCT (CR to salvage chemotherapy) 8
Volume of RT (after CR to chemotherapy)
 RT (ISRT) to site of relapse 8
 Adjuvant RT to recurrent and all previously untreated nodal sites (TLI) 4
Timing of RT
 Primary therapy 2
 Following salvage chemotherapy, if no SCT 5
 After salvage chemotherapy, before SCT (CR to salvage chemotherapy) 7
 After SCT 7
RT dose to mediastinum (CR to salvage chemotherapy)
 < 30 Gy 4
 30–36 Gy 7
 > 36 Gy 6
Rating Scale: 1,2,3 = usually not appropriate; 4,5,6 = may be appropriate; 7,8,9 = usually appropriate.
ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; CR = complete response; CS = clinical stage; ISRT = involved-site radiation 
therapy; NSHL = nodular sclerosis Hodgkin lymphoma; PET = positron emission tomography; RT = radiation therapy; SCT = stem cell 
transplantation; TLI = total lymphoid irradiation.
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VARIANT 6.
25-year-old woman with CS IIIAX (neck, bulky mediastinum, upper para-aortic) NSHL was treated with 
ABVD. After 6 cycles of ABVD, the mediastinal disease regressed by 33% and mass remained FDG avid 
[Deauville 4]. (Incomplete response to chemotherapy.)
Treatment Rating Comments
Evidence for relapse or refractory disease
 Requires pathologic confirmation 7
Recommended treatment
 RT alone 5
 Salvage chemotherapy only 5
 Salvage chemotherapy + RT 5
 Salvage chemotherapy + SCT 7
 Salvage chemotherapy + RT + SCT (CR to salvage chemotherapy) 7
Volume of RT (after CR to chemotherapy)
 RT (ISRT) to site of relapse 8
 Adjuvant RT to recurrent and all previously untreated nodal sites (TLI) 3
Timing of RT
 Primary therapy 5
 Following salvage chemotherapy, if no SCT 5
 After salvage chemotherapy, before SCT (CR to salvage chemotherapy) 6
 After SCT 7
RT dose to mediastinum (CR to salvage chemotherapy)
 < 30 Gy 3
 30–36 Gy 7
 > 36 Gy 7
Rating Scale: 1,2,3 = usually not appropriate; 4,5,6 = may be appropriate; 7,8,9 = usually appropriate.
ABVD = doxorubicin, bleomycin, vinblastine, and dacarbazine; CR = complete response; CS = clinical stage; FDG = 2-fluoro-2-deoxy-D-glucose; 
ISRT = involved-site radiation therapy; NSHL = nodular sclerosis Hodgkin lymphoma; RT = radiation therapy; SCT = stem cell 
transplantation;TLI = total lymphoid irradiation.
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